Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Lorcaserin for Treating Patients with Dravet Syndrome (Epilepsy)

Research Question:
Does the drug, lorcaserin, affect the frequency of convulsive seizures in patients with Dravet syndrome?

Basic Study Information

Purpose:
There is a Core Study and an Extension Phase. The Core Study will include a Pre-randomization (Baseline) and a Randomization (Treatment) Phase. The Pre-randomization Phase will include a Screening/Baseline Period (4 weeks), during which the subjects will be assessed for eligibility. Once the Screening and Baseline procedures have been completed and eligibility has been established, the subjects will be randomized to 1 of 2 treatment groups in a ratio of 1:1 and will receive lorcaserin or placebo for 14 weeks. All subjects who complete the Core Study will be eligible to enter the 16-week Open-label Extension Phase. Eligibility: Aged 2 or older with a diagnosis of Dravet syndrome.

Study Reference #: 5376

Lead Researcher (Principal Investigator)

Lead Researcher:  Inna Hughes

Study Contact Information

Study Coordinator: Noreen Connolly
Phone: (585) 275-0589
Email: noreen_connolly@urmc.rochester.edu

Additional Study Details

Number of Visits:  6 to 10
Parking:  Free
Transportation Coverage:  Yes
Reimbursement:  No

Learn More About These Conditions

More information about Epilepsy

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search